HighTide Therapeutics Inc
Company Profile
Business description
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Contact
Building D, Guangdong
Floor 9 to 10, Fubao Community, Futian District
Shenzhen-Hong Kong Science and
Technology Innovation Cooperation Zone
Shenzhen518112
CHNT: +86 75526626253
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
70
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,590.90 | 19.50 | 0.23% |
| CAC 40 | 7,864.44 | 46.05 | -0.58% |
| DAX 40 | 23,999.17 | 123.23 | -0.51% |
| Dow JONES (US) | 41,859.09 | 1.35 | -0.00% |
| FTSE 100 | 8,739.26 | 47.20 | -0.54% |
| HKSE | 23,628.02 | 83.71 | 0.36% |
| NASDAQ | 18,925.73 | 53.09 | 0.28% |
| Nikkei 225 | 37,241.45 | 255.58 | 0.69% |
| NZX 50 Index | 12,609.05 | 53.20 | -0.42% |
| S&P 500 | 5,842.01 | 2.60 | -0.04% |
| S&P/ASX 200 | 8,365.80 | 17.10 | 0.20% |
| SSE Composite Index | 3,383.32 | 3.13 | 0.09% |